{"analyses":[{"ciNumSides":"TWO_SIDED","estimateComment":"Bupropion adherent individuals with higher hydroxybupropion levels were more likely to be abstinent at Weeks 3, 7 and 26 compared to individuals with lower hydroxybupropion levels.","groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"<0.05","pValueComment":"Analysis relied on examining quit rates using linear regression, where the hydroxybupropion was a significant predictor of smoking cessation. CYP2B6 genotype was not a direct significant predictor of cessation in either the placebo or bupropion arm.","paramType":"Odds Ratio (OR)","paramValue":"2.82","statisticalMethod":"Regression, Linear"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"CYP2B6*4 Allele Frequency"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"CYP2B6*5 Allele Frequency"},{"categories":[{"measurements":[{"groupId":"OG000","value":"95"}]}],"title":"CYP2B6*6 Allele Frequency"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"CYP2B6*9 Allele Frequency"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"CYP2B6*16 Allele Frequency"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"CYP2B6*18 Allele Frequency"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"CYP2B6*22 Allele Frequency"}],"denoms":[{"counts":[{"groupId":"OG000","value":"268"}],"units":"Participants"}],"description":"We genotyped CYP2B6 in 268 from the Bupropion arm as this polymorphism is related to bupropion metabolism.","groups":[{"description":"270 African American adults received bupropion (150mg bid)for 7 weeks in addition to health education counseling.","id":"OG000","title":"Bupropion Arm"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Week 3","title":"Number of Participants for Each CYP2B6 Allele","type":"SECONDARY","unitOfMeasure":"Participants"}